Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
J Neurointerv Surg. 2022 Mar;14(3):257-261. doi: 10.1136/neurintsurg-2020-017089. Epub 2021 Apr 27.
The ideal treatment for unruptured vertebral artery dissecting aneurysms (VADAs) and ruptured dominant VADAs remains controversial. We report our experience in the management and endovascular treatment of patients with VADAs.
Patients treated endovascularly for intradural VADAs at a single institution from January 1, 1999, to December 31, 2019, were retrospectively reviewed. Primary neurological outcomes were assessed using modified Rankin Scale (mRS) scores, with mRS >2 considered a poor neurological outcome. Additionally, any worsening (increase) in the mRS score from the preoperative neurological examination was considered a poor outcome.
Ninety-one patients of mean (SD) age 53 (11.6) years (48 (53%) men) underwent endovascular treatment for VADAs. Fifty-four patients (59%) presented with ruptured VADAs and 44 VADAs (48%) involved the dominant vertebral artery. Forty-seven patients (51%) were treated with vessel sacrifice of the parent artery, 29 (32%) with flow diversion devices (FDDs), and 15 (17%) with stent-assisted coil embolization (stent/coil). Rates of procedural complications and retreatment were significantly higher with stent/coil treatment (complications 4/15; retreatment 6/15) than with vessel sacrifice (complications 1/47; retreatment 2/47) or FDD (complications 2/29; retreatment 4/29) (p=0.008 and p=0.002, respectively). Of 37 patients with unruptured VADAs treated, only two (5%) had mRS scores >2 on follow-up.
Endovascular FDD treatment of VADAs appears to be associated with lower retreatment and complication rates than stenting/coiling, although further study is required for confirmation. Endovascular treatment of unruptured VADAs was safe and was associated with favorable angiographic and neurological outcomes.
未破裂椎动脉夹层动脉瘤(VADA)和破裂优势椎动脉 VADA 的理想治疗方法仍存在争议。我们报告了在单一机构中对 VADA 患者进行管理和血管内治疗的经验。
回顾性分析 1999 年 1 月 1 日至 2019 年 12 月 31 日期间在一家机构接受血管内治疗的颅内 VADA 患者。使用改良 Rankin 量表(mRS)评分评估主要神经功能预后,mRS>2 被认为是不良神经功能预后。此外,术前神经检查时 mRS 评分增加(恶化)被认为是不良预后。
91 例平均(标准差)年龄 53(11.6)岁(48[53%]名男性)患者因 VADA 接受血管内治疗。54 例(59%)患者为破裂性 VADA,44 例 VADA(48%)累及优势椎动脉。47 例(51%)患者行载瘤动脉血管内闭塞治疗,29 例(32%)行血流导向装置(FDD)治疗,15 例(17%)行支架辅助弹簧圈栓塞(支架/线圈)治疗。支架/线圈治疗的手术并发症和再治疗率明显高于载瘤动脉血管内闭塞治疗(并发症 4/15;再治疗 6/15)和 FDD 治疗(并发症 2/29;再治疗 4/29)(p=0.008 和 p=0.002)。37 例未破裂 VADA 患者中,仅 2 例(5%)在随访时 mRS 评分>2。
与支架/线圈治疗相比,血管内 FDD 治疗 VADA 似乎与较低的再治疗和并发症发生率相关,但需要进一步研究证实。血管内治疗未破裂 VADA 是安全的,并且与有利的血管造影和神经功能结果相关。